It is alleged in this complaint that during the class period, Zosano Pharma Corporation made materially misleading and/or false statements and/or failed to disclose that: (1) Zosano’s clinical results reflected differences in zolmitriptan exposures that had been observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with Zolsano’s New Drug Application included patients that had exhibited unexpected high plasma concentrations of zolmitriptan; (3) it was reasonably likely that the U.S. Food and Drug Administration would require further studies to support regulatory approval of the Zolsano’s lead product candidate, Qtrypta, as a result of the foregoing differences among patient results; (4) regulatory approval of Qtrypta was reasonably likely to be delayed as a result; and (5) Defendants’ public statements were materially misleading and false at all relevant times, as a result of the foregoing.

Zosano Pharma Corporation

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.

Are you a current or former employee of the company?*YesNo

Purchases

+Additional Purchases

Sales

+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:




There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com